Skip to main content
Clinical Trials/ISRCTN16559899
ISRCTN16559899
Completed
N/A

A Multicentre Randomised and Comparative Trial to Assess the Tolerance, Efficacy and Pharmacokinetics of Escalating Doses of Casodex Versus Castration in the Treatment of Advanced Carcinoma of the Prostate

AstraZeneca Clinical Research Group (UK)0 sites248 target enrollmentAugust 19, 2002

Overview

Phase
N/A
Intervention
Not specified
Conditions
Prostate cancer
Sponsor
AstraZeneca Clinical Research Group (UK)
Enrollment
248
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

2006 results in: https://www.ncbi.nlm.nih.gov/pubmed/16771791 (added 29/10/2019)

Registry
who.int
Start Date
August 19, 2002
End Date
September 11, 1996
Last Updated
6 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
AstraZeneca Clinical Research Group (UK)

Eligibility Criteria

Inclusion Criteria

  • 1\. Histologically/cytologically confirmed metastatic or locally advanced (T3 or T4\) prostate carcinoma. Confirmed within the last month
  • 2\. Life expectancy of more than 3 months
  • 3\. Prostate specific antigen (PSA) of at least five\-times upper limit of normal reference range
  • 4\. Evaluable disease and fit to receive any of the treatment options
  • 5\. No previous or concurrent systemic therapy for prostate cancer
  • 6\. No radiotherapy to the prostate within the 3 months prior to entry into the trial
  • 7\. No previous medical history of another malignancy within the past 5 years
  • 8\. Adequate cardiac, renal and hepatic function
  • 9\. Eastern Cooperative Oncology Group (ECOG) performance 3 or 4

Exclusion Criteria

  • Not provided at time of registration

Outcomes

Primary Outcomes

Not specified

Similar Trials